A230065H16Rik Inhibitors
Chemical inhibitors of LBH domain containing 2 (LBHDC2) function through various molecular mechanisms to hinder the activity of the protein. Alizarin operates by chelating divalent metal ions like calcium, which are crucial for maintaining the structural integrity and functionality of LBHDC2. Similarly, Genistein targets tyrosine kinases that are essential upstream regulators in the cellular pathways involving LBHDC2. By inhibiting these kinases, Genistein prevents the activation or necessary phosphorylation of LBHDC2, leading to its functional inhibition. Staurosporine, a broad-spectrum kinase inhibitor, suppresses a variety of kinases that might phosphorylate LBHDC2, thereby interfering with the protein's kinase-dependent activities.
In parallel, LY294002 and Wortmannin are both inhibitors of phosphoinositide 3-kinases (PI3K), which are part of the signaling cascade crucial for the activation of LBHDC2. By blocking PI3K, these inhibitors disrupt downstream signaling pathways that are vital for LBHDC2's activation. Rapamycin specifically inhibits the mammalian target of rapamycin (mTOR), a kinase that can indirectly affect LBHDC2's functionality by modulating growth factor signaling pathways. Furthermore, PD98059 and U0126 are inhibitors of mitogen-activated protein kinase kinase (MEK), which is a component of the MAPK/ERK pathway. Inhibition of this pathway by these chemicals leads to reduced downstream signaling and consequent inactivation of LBHDC2. Additionally, SB203580 targets p38 MAP kinase and SP600125 inhibits c-Jun N-terminal kinase (JNK), both of which are involved in stress response and other signaling pathways that regulate the activity of LBHDC2. Lastly, NF449 blocks G-protein-coupled receptor signaling by antagonizing the Gs-alpha subunit, thereby inhibiting the cellular signaling processes that involve LBHDC2. Each of these chemicals disrupts specific molecular interactions or signaling pathways that are necessary for the proper functioning of LBHDC2, resulting in its inhibition.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alizarin | 72-48-0 | sc-214519 sc-214519A | 1.5 g 100 g | $21.00 $50.00 | ||
Alizarin inhibits the LBH domain containing 2 by chelating divalent metal ions such as calcium that are necessary for the protein's structural stability and function. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein inhibits tyrosine kinases which are upstream regulators in cellular pathways that LBH domain containing 2 is involved in, leading to the functional inhibition of LBH domain containing 2 by preventing its activation or phosphorylation necessary for its activity. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a potent kinase inhibitor that inhibits numerous kinases that may phosphorylate LBH domain containing 2, thereby inhibiting the protein's activity through deactivation of its kinase-dependent functions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 inhibits PI3K, which is part of the signaling pathway that activates LBH domain containing 2, leading to the inhibition of LBH domain containing 2 by hindering its essential signaling-mediated activation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits mTOR, a kinase that can indirectly influence the activity of LBH domain containing 2 by affecting growth factor signaling pathways that regulate the protein's function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 inhibits MEK, which is part of the MAPK/ERK pathway, leading to the inhibition of downstream signaling that would otherwise contribute to the functional activation of LBH domain containing 2. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which may regulate the activity of LBH domain containing 2 through stress response signaling pathways, leading to the functional inhibition of LBH domain containing 2. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, which is involved in signaling pathways that regulate the activity of LBH domain containing 2, thus inhibiting the protein's activity by preventing its regulation by JNK-mediated signals. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is an inhibitor of MEK1/2, preventing the activation of the MAPK/ERK pathway, which plays a role in the signaling that contributes to the functional activity of LBH domain containing 2, thus inhibiting the protein. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is a PI3K inhibitor, which disrupts the PI3K/Akt pathway that is essential for the activation of several proteins, including LBH domain containing 2, leading to its functional inhibition. | ||||||